Drug Pipeline

Drug Pipeline Market Research Reports

1 . Drug Pipeline Market Research Reports Analysis and Trends

Discovering and bringing new drugs to mainstream commercial market typically takes an average of 10-15 years of research and clinical development efforts. Drug developers need to make sure safe and effective drug available for patient in quick time. The first step is to target the protein available in the patient’s body that is associated with microorganism causing a disease, through tracking of cellular network of proteins an appropriate target for a drug is selected. Through a series of trials, right drug candidate got chosen.
 
According to “NOVARTIS”, bringing a new drug in market takes 14 years of research and cost around USD 2 billion, 10K+ clinical trials out of these, one leads to successful drug development.
Titlesort descending Published Pages Price
Allergic Rhino-Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players May 2 2022 43 USD 2,000.00
Allergy Drugs Companies in China Mar 12 2018 50 USD 1,800.00
Allergy Drugs Industry Forecasts - China Focus Mar 12 2018 108 USD 1,800.00
Allergy Drugs Markets in China Mar 12 2018 207 USD 4,000.00
Alopecia (Dermatology) - Drugs in Development, 2021 Mar 31 2021 249 USD 2,500.00
Alopecia - Pipeline Review, H1 2019 Mar 18 2019 160 USD 2,000.00
Alopecia - Pipeline Review, H1 2020 Jan 14 2020 190 USD 2,000.00
Alopecia - Pipeline Review, H2 2018 Jul 17 2018 163 USD 2,000.00
Alopecia - Pipeline Review, H2 2019 Nov 18 2019 184 USD 2,000.00
Alopecia - Pipeline Review, H2 2020 Jul 31 2020 222 USD 2,000.00
Alopecia Areata (Dermatology) - Drugs in Development, 2021 Apr 30 2021 60 USD 2,000.00
Alopecia Areata Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players May 2 2022 60 USD 2,000.00
Alopecia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Mar 31 2022 186 USD 2,000.00
Alpha 1 Adrenergic Receptor (ADRA1) - Drugs in Development, 2021 Apr 30 2021 60 USD 3,000.00
Alpha 1 Adrenergic Receptor (ADRA1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players May 2 2022 67 USD 2,500.00
Alpha 1 Antitrypsin (Alpha 1 Protease Inhibitor or Alpha 1 Antiproteinase or SERPINA1) - Drugs in Development, 2021 Apr 30 2021 60 USD 3,000.00
Alpha 1 Antitrypsin (Alpha 1 Protease Inhibitor or Alpha 1 Antiproteinase or SERPINA1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players May 2 2022 64 USD 2,500.00
Alpha 1A Adrenergic Receptor (Alpha 1A Adrenoreceptor or Alpha 1C Adrenergic Receptor or Alpha Adrenergic Receptor 1c or ADRA1A) - Drugs in Development, 2021 Apr 30 2021 35 USD 3,000.00
Alpha 1A Adrenergic Receptor (Alpha 1A Adrenoreceptor or Alpha 1C Adrenergic Receptor or Alpha Adrenergic Receptor 1c or ADRA1A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players May 2 2022 39 USD 2,500.00
Alpha 1B Adrenergic Receptor (Alpha 1B Adrenoreceptor or ADRA1B) - Drugs in Development, 2021 Apr 30 2021 35 USD 3,000.00
Alpha 1B Adrenergic Receptor (Alpha 1B Adrenoreceptor or ADRA1B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players May 2 2022 37 USD 2,500.00
Alpha 1D Adrenergic Receptor (Alpha 1A Adrenergic Receptor or Alpha 1D Adrenoreceptor or Alpha Adrenergic Receptor 1a or ADRA1D) - Drugs in Development, 2021 Apr 30 2021 30 USD 3,000.00
Alpha 2 Adrenergic Receptor (ADRA2) - Drugs in Development, 2021 Apr 30 2021 60 USD 3,000.00
Alpha 2 Adrenergic Receptor (ADRA2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players May 2 2022 68 USD 2,500.00
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Drugs In Development, 2021 Dec 30 2021 55 USD 3,500.00
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Dec 28 2022 51 USD 3,500.00
Alpha 2C Adrenergic Receptor - Pipeline Review, H1 2020 Jun 30 2020 50 USD 3,500.00
Alpha 2C Adrenergic Receptor - Pipeline Review, H2 2019 Dec 27 2019 49 USD 3,500.00
Alpha Adrenergic Receptor (ADRA) - Drugs in Development, 2021 Apr 30 2021 30 USD 3,000.00
Alpha Adrenergic Receptor (ADRA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players May 2 2022 101 USD 2,500.00
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Pipeline Review, H1 2018 Apr 10 2018 68 USD 3,500.00
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Pipeline Review, H2 2018 Oct 16 2018 72 USD 3,500.00
Alpha Galactosidase A - Pipeline Review, H2 2019 Dec 27 2019 84 USD 3,500.00
Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Drugs In Development, 2021 Jun 30 2021 68 USD 3,500.00
Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Pipeline Review, H1 2018 Jun 12 2018 52 USD 3,500.00
Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Mar 31 2022 62 USD 3,500.00
Alpha L-Iduronidase - Pipeline Review, H1 2020 Feb 28 2020 64 USD 3,500.00
Alpha L-Iduronidase - Pipeline Review, H2 2019 Dec 27 2019 63 USD 3,500.00
Alpha L-Iduronidase - Pipeline Review, H2 2020 Aug 31 2020 66 USD 3,500.00
Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase or NAGLU or EC 3.2.1.50) - Drugs In Development, 2021 Dec 30 2021 62 USD 3,500.00
Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase or NAGLU or EC 3.2.1.50) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Dec 28 2022 49 USD 3,500.00
Alpha N-Acetylglucosaminidase - Pipeline Review, H1 2020 Jun 30 2020 54 USD 3,500.00
Alpha N-Acetylglucosaminidase - Pipeline Review, H2 2019 Dec 27 2019 52 USD 3,500.00
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Pipeline Review, H1 2018 Jan 31 2018 101 USD 3,500.00
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Pipeline Review, H1 2019 Apr 29 2019 123 USD 3,500.00
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Pipeline Review, H2 2018 Jul 10 2018 101 USD 3,500.00
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 159 USD 3,500.00
Alpha Synuclein - Pipeline Review, H1 2020 Jun 30 2020 150 USD 3,500.00
Alpha Synuclein - Pipeline Review, H2 2019 Aug 30 2019 126 USD 3,500.00
Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2018 Feb 27 2018 84 USD 2,000.00

Clients Who Trust Us

Market Research Reports Inc. Customers

Need tailor made market research solution? We can help you with that too.

About Us

At Market Research Reports, Inc. we aim to make it easier for decision makers to find relevant information and locate right market research reports which can save their time and assist in what they do best, i.e. take time-critical decisions.

We work with our associate Global market research firms who are known leaders in their respective domains to obtain right market research solution for our customer’s needs, be it custom research or syndicated research reports.

Contact Us

Market Research Reports, Inc
16192 Coastal Hwy
Lewes
, DE 19958, USA

USA: +1-302-703-9904

India: +91-8762746600

marketresearchreports

info@marketresearchreports.com

User login

Stay Connected